Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. The company develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. It also develops oral small molecule single- and multi-incretin receptor agonists for metabolic disorders including obesity and type 2 diabetes. In addition, the company focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease. Septerna, Inc. was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. The company was incorporated in 2019 and is headquartered in South San Francisco, California.

Septerna, Inc.

An announcement from SSE ( ($GB:SSE) ) is now available. SSE has disclosed that Chair Sir John Manzoni has increased his shareholding through parti...

SSE Chair boosts stake via scrip dividend participation

In a report released today, from Berenberg Bank reiterated a Buy rating on SSE, with a price target of p2,980.00. In addition to Berenberg Bank, SS...

Berenberg Bank Keeps Their Buy Rating on SSE (SSE)

In a report released today, Derek Archila from Wells Fargo maintained a Buy rating on Septerna, Inc., with a price target of $50.00. According to T...

Wells Fargo Sticks to Their Buy Rating for Septerna, Inc. (SEPN)

While many investors remain focused on large-cap stocks, some smaller companies could offer greater upside potential. Analysts are bullish on sever...

3 Small-Cap Stocks to Buy with 35%+ Upside, According to Analysts

SSE ( ($GB:SSE) ) has provided an announcement. SSE plc has disclosed that several directors and persons discharging managerial responsibilities ac...

SSE Directors and Senior Managers Acquire Shares Under Incentive Plan

Deutsche Bank analyst James Brand reiterated a Buy rating on SSE today and set a price target of p2,650.00. According to TipRanks, Brand is a 5-sta...

Deutsche Bank  Remains a Buy on SSE (SSE)

An announcement from SSE ( ($GB:SSE) ) is now available. SSE plc has reported that 22,138 shareholders elected to receive the final dividend for th...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SEPN	$37.77	-0.94%	344.28K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SEPN	$37.77	-0.9%	344.28K
3
4
5
6

SEPN

Get Septerna, Inc. Data in Excel

Get Septerna, Inc. Data in Excel